A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

Mylan on Tuesday earned Food and Drug Administration approval for its generic version of Teva’s multiple sclerosis drug Copaxone. 1. Mylan’s glatiramer acetate injection is intended to treat patients ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

TEVA beats EPS estimates but revenue misses and guidance is weak. Generic price competition and weak new product launches pressure revenue growth. Copaxone is better than expected but a forthcoming ...

In denying the eighth citizen petition filed by Teva Pharmaceutical Industries Ltd. to protect its blockbuster multiple sclerosis (MS) drug Copaxone from generic competition, the FDA followed a hard ...

San Antonio’s H-E-B and other major retailers have teamed up to wage legal battles on both coasts against pharmaceutical companies for allegedly monopolizing the market for certain prescription drugs.

(Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it is "completely confident" the new version of its flagship multiple sclerosis drug, Copaxone, which features less frequent dosing, will ...